Louise Rodino-Klapac - Sep 3, 2025 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
President, R&D and Tech Ops
Signature
/s/ Cristin Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac
Stock symbol
SRPT
Transactions as of
Sep 3, 2025
Transactions value $
$0
Form type
4
Date filed
9/5/2025, 09:30 PM
Previous filing
Aug 6, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rodino-Klapac Louise President, R&D and Tech Ops 215 FIRST STREET, SUITE 415, CAMBRIDGE /s/ Cristin Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac 2025-09-05 0001836218

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Award $0 +93.9K +110.78% $0.00 179K Sep 3, 2025 Direct F1, F2
transaction SRPT Common Stock Award $0 +50K +27.99% $0.00 229K Sep 3, 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 50% of the RSUs will vest on September 3, 2026, and the remaining 50% will vest on September 3, 2027, subject to the Reporting Person's continued service to the Company.
F2 Includes 106 shares of common stock purchased on August 31, 2025 through the Company's Employee Stock Purchase Plan
F3 The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 100% of the RSUs will vest on September 3, 2028, subject to the Reporting Person's continued service to the Company and only if certain performance criteria has been deemed achieved by the Compensation Committee of the Board.